Lilly’s Lepodisiran Slashes Heart Disease Risk Factor by 94% in Phase 2 Trial
Eli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreResearchers and scientists worldwide can now access Evo 2, a massive new foundation model that deciphers the genetic code across
Read moreAdvanced single-cell technologies, particularly methods such as single-cell RNA sequencing (scRNA-seq), coupled with sophisticated computational tools and the increasing accessibility
Read more3-D Life Dextranase developed by Cellendes allows non-toxic recovery of cells from dextran-based 3-D Life Hydrogels without harming the cells
Read moreMerck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre
Read morePreclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read moreAmerican biotech company Ginkgo Bioworks announced a new collaboration with Pfizer focused on the discovery of RNA-based drug candidates. The
Read moreIn a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreTransCode Therapeutics and BRAIN Biotech have entered a joint research and development agreement (JDA) with the objective to co-develop a
Read moreThe construction of BioNTech’s first in-house plasmid DNA processing plant in Marburg, Germany, has now been completed, the company announced
Read more